Hydroxychloroquine Retinopathy Screening: Dose, Timing and Tests

Hydroxychloroquine Retinopathy Screening: Dose, Timing and Tests

For: PG residents · Practising ophthalmologists

Last updated: November 2026

Key points in 60 seconds

  • 5 × 5 rule: dose under 5 mg/kg/day of actual body weight; annual screening from 5 years of use.
  • Start screening after 1 year if there are risk factors (renal disease, tamoxifen, macular disease); chloroquine from 1 year in everyone.
  • Use SD-OCT and automated fields (plus FAF and mfERG as needed); Asian patients may show a pericentral pattern.
  • Toxicity is irreversible and can progress after stopping: the aim is to catch it before symptoms.

Hydroxychloroquine is widely used for lupus, rheumatoid arthritis and other autoimmune diseases. It can cause an irreversible retinopathy that keeps progressing even after the drug is stopped, so the goal of screening is to catch it before the patient notices any change. Here is the current approach, based on the Royal College of Ophthalmologists (2020) and the American Academy of Ophthalmology (2016) recommendations.

The 5 × 5 rule

Dose under 5 mg/kg/dayCalculated on actual body weight. The risk rises steeply above this dose.
Screen after 5 yearsAnnual monitoring from 5 years of use, or after 1 year if there are additional risk factors. Chloroquine: from 1 year in everyone.
Risk factorEffect
Dose above 5 mg/kg/day (actual weight)The main risk factor
Duration over 5 yearsRisk rises with cumulative dose: under 2% in the first 10 years at recommended doses, about 20% after 20 years (Melles and Marmor 2014)
Reduced kidney function (eGFR below 60)Less drug excretion
TamoxifenIncreases retinal toxicity
Pre-existing macular diseaseMakes screening harder to interpret

Who, when and how

QuestionAnswer (RCOphth 2020)
Baseline examination?No longer recommended routinely in the UK. The AAO recommends a baseline fundus examination within the first year, with fields and OCT if maculopathy is present; many Indian units still record a baseline OCT.
When to start annual screening?After 5 years of hydroxychloroquine; after 1 year if dose above 5 mg/kg/day, eGFR below 60, or on tamoxifen; after 1 year for chloroquine.
Which tests?Spectral-domain OCT of the macula and widefield fundus autofluorescence (FAF) at each visit. Visual fields (10-2, and 24-2 or 30-2 in Asian patients) are used when imaging is abnormal or doubtful.
Who is responsible?The prescriber refers the patient and acts on the result; the eye service reports normal, possible or definite retinopathy.

What does toxicity look like?

  • OCT: thinning or loss of the ellipsoid zone and outer nuclear layer, first in a parafoveal ring (the "flying saucer" sign of preserved central foveal tissue).
  • Asian patients often show a pericentral pattern further out, along the arcades, which is why a wider field (24-2 or 30-2, and widefield FAF) is needed.
  • FAF: a ring of increased then decreased autofluorescence.
  • Late: bull's eye maculopathy, visible on examination, with permanent central field loss.
  • Cornea: vortex keratopathy (verticillata) is harmless and not a reason to stop.

If retinopathy is found

  • Definite retinopathy: inform the prescriber promptly; stopping the drug is the only intervention, and the decision is shared with the patient and rheumatologist.
  • Possible retinopathy: repeat tests (often with fields and multifocal ERG) within a few months.
  • Damage may progress for a while after stopping, so early detection matters.

Where residents slip

  • Calculating the dose on ideal instead of actual body weight (the AAO 2016 change).
  • Using only a 10-2 field in Asian patients and missing pericentral toxicity.
  • Stopping the drug for vortex keratopathy.
  • Relying on fundus examination alone: bull's eye maculopathy is a late sign.

Key sources

  • Yusuf IH, et al. Hydroxychloroquine and chloroquine retinopathy: recommendations on monitoring. Royal College of Ophthalmologists; December 2020. rcophth.ac.uk
  • Marmor MF, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386-1394
  • Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453-1460

Related: Screening schedules, Ocular side effects of systemic drugs, OCT macula reference.

📘 Want more exam-ready material? See Most Commons in Ophthalmology on Kindle, or browse all my books.

How to cite this page

Patel D. Hydroxychloroquine Retinopathy Screening: Dose, Timing and Tests. RPC Rounds (Sadbhaav Eye Clinic). Updated November 2026. Available at: https://www.sadbhaavclinic.com/hydroxychloroquine-screening.html. Accessed [date].

Written and medically reviewed by Dr. Dhaval Patel, MD (Ophthalmology, AIIMS New Delhi) · Editorial policy

Consultant, Cataract & Refractive Surgery — among a small number of AIIMS-trained ophthalmologists practicing in Gujarat. Read full credentials & experience or view his 28 publications on ResearchGate.

📚 Also the author of OKAT Decoded, FRCOphth Decoded, FICO Decoded, OKAP & ABO Decoded, FEBO Decoded and other high-yield ophthalmology exam-prep books used by residents and PG aspirants.

Looking for an eye specialist in Ahmedabad? Learn about our Eye Department or book a consultation with Dr. Dhaval Patel.